Novel Therapeutic Trends in Pneumonia: Antibiotics and Mesenchymal Stem Cells

J. Ly, Q. Chu, L. Zhong
{"title":"Novel Therapeutic Trends in Pneumonia: Antibiotics and Mesenchymal Stem Cells","authors":"J. Ly, Q. Chu, L. Zhong","doi":"10.20944/PREPRINTS202104.0031.V1","DOIUrl":null,"url":null,"abstract":"Pneumonia remains a major cause of morbidity and mortality worldwide, especially during COVID-19 pandemic. With the significant global health burden that pneumonia poses, it is es-sential to improve therapeutic and management strategies. The increasing emergence of antibiotic resistant bacterial strains limits options for effective antibiotic use. New antibiotics for treatment of pneumonia may address deficits in current antimicrobial drugs, with an ability to cover both typical, atypical, and resistance pathogen. Several of these newer drugs also have structural characteristics that allow for a decreased propensity in development of bacterial resistance. Po-tential use of stem cell therapies in place of corticosteroid treatments may also offer an im-provement in patient outcomes. Human mesenchymal stem cell treatments have shown efficacy and safety in treating COVID-19 induced pneumonia. Combined treatment with both stem cells and antibiotics in pneumonia in a rabbit model has also shown significantly increased efficacy in comparison to antibiotic treatment alone, presenting yet another possible route for a novel strategy in treating pneumonia, though additional future studies are necessary before clinical implementation. While pneumonia remains a major disease of concern, having newer approved antibiotics as well as novel therapies such as stem cell treatments in the pipeline offers clinicians more options in effectively treating pneumonia.","PeriodicalId":72392,"journal":{"name":"Biomedical research and clinical reviews","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical research and clinical reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20944/PREPRINTS202104.0031.V1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Pneumonia remains a major cause of morbidity and mortality worldwide, especially during COVID-19 pandemic. With the significant global health burden that pneumonia poses, it is es-sential to improve therapeutic and management strategies. The increasing emergence of antibiotic resistant bacterial strains limits options for effective antibiotic use. New antibiotics for treatment of pneumonia may address deficits in current antimicrobial drugs, with an ability to cover both typical, atypical, and resistance pathogen. Several of these newer drugs also have structural characteristics that allow for a decreased propensity in development of bacterial resistance. Po-tential use of stem cell therapies in place of corticosteroid treatments may also offer an im-provement in patient outcomes. Human mesenchymal stem cell treatments have shown efficacy and safety in treating COVID-19 induced pneumonia. Combined treatment with both stem cells and antibiotics in pneumonia in a rabbit model has also shown significantly increased efficacy in comparison to antibiotic treatment alone, presenting yet another possible route for a novel strategy in treating pneumonia, though additional future studies are necessary before clinical implementation. While pneumonia remains a major disease of concern, having newer approved antibiotics as well as novel therapies such as stem cell treatments in the pipeline offers clinicians more options in effectively treating pneumonia.
肺炎治疗新趋势:抗生素和间充质干细胞
肺炎仍然是全球发病率和死亡率的主要原因,尤其是在新冠肺炎大流行期间。肺炎给全球带来了巨大的健康负担,因此有必要改进治疗和管理策略。抗生素耐药性菌株的日益出现限制了有效使用抗生素的选择。用于治疗肺炎的新型抗生素可能会解决目前抗菌药物的不足,能够覆盖典型、非典型和耐药性病原体。这些新药物中的一些还具有结构特征,可以降低细菌耐药性的发展倾向。经常使用干细胞疗法代替皮质类固醇治疗也可能改善患者的预后。人类间充质干细胞治疗在治疗新冠肺炎诱导的肺炎方面显示出有效性和安全性。在兔模型中,与单独的抗生素治疗相比,干细胞和抗生素联合治疗肺炎的疗效也显著提高,这为治疗肺炎的新策略提供了另一种可能的途径,尽管在临床实施之前还需要进一步的未来研究。虽然肺炎仍然是一种令人担忧的主要疾病,但新批准的抗生素以及干细胞治疗等新疗法正在酝酿中,为临床医生有效治疗肺炎提供了更多选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信